Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients

NCT04122976 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04122976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04122976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
Lead sponsor
Bayer
Phase
Observational
Overall status
Active, not recruiting
Start date
January 30, 2020
Completion date
October 7, 2026
Enrollment
805 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer